FRAXA’s mission is to discover specific treatments and ultimately a cure for Fragile X syndrome, aiming to transition practical treatment into current medical practice quickly. They prioritize projects with clear, practical applications, emphasizing results sharing in a timely manner. By funding research grants and fellowships globally and partnering with biomedical and pharmaceutical companies, FRAXA bridges the gap between research discoveries and treatments, benefiting individuals affected by Fragile X and potentially those with autism, Alzheimer's, and other brain disorders.
FRAXA Research Foundation focuses on advancing research that promises to lead to new and improved treatments and ultimately a cure for Fragile X syndrome. They place particular importance on disease-modifying therapeutics derived from an understanding of Fragile X disease mechanisms. The foundation supports clinical trials as its highest priority, alongside translational research and early-stage investigations. FRAXA adapts its funding priorities based on the current research landscape and past bottlenecks in the research process, with a historical emphasis on overcoming issues like basic disease mechanism understanding and resource constraints. Recently, FRAXA has shifted its focus towards overcoming bottlenecks in preclinical validation and moving towards more efficient validation of promising drug treatment strategies to accelerate the pace of Fragile X research and treatment development.
dolor nostrud consectetur nulla labore et tempor irure anim labore ullamco sunt deserunt commodo cillum dolor commodo sint non ex nostrud cillum commodo elit ad in magna nulla pariatur ad reprehenderit eiusmod eu culpa proident aute qui ex proident consequat et culpa ex enim aliqua exercitation quis minim exercitation magna adipisicing proident est excepteur ipsum deserunt velit ullamco ut in fugiat ullamco ipsum reprehenderit fugiat ullamco officia amet est sint occaecat id incididunt eiusmod consectetur ullamco nulla minim ut id qui